Evidence map›Paper›PMID 40467649›Full record

ArticleScientific reports2025

Development of a microarray based telomerase binding assay reveals unusual binding of a cytochalasin derivative.

Jia Li Ye, Lu Fan, Christian Bär, Thomas Thum, Oliver Plettenburg, Russell J Cox, Carsten Zeilinger

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jia Li YeHannover Medical School, Institute of Molecular and Translational Therapeutic Strategies, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Lu FanCentre of Biomolecular Drug Research (BMWZ) and Institute for Organic Chemistry, Gottfried-Wilhelm-Leibniz University Hannover, Schneiderberg 38, 30167, Hannover, Germany.
Christian BärHannover Medical School, Institute of Molecular and Translational Therapeutic Strategies, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Thomas ThumHannover Medical School, Institute of Molecular and Translational Therapeutic Strategies, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Oliver PlettenburgCentre of Biomolecular Drug Research (BMWZ) and Institute for Organic Chemistry, Gottfried-Wilhelm-Leibniz University Hannover, Schneiderberg 38, 30167, Hannover, Germany.
Russell J CoxCentre of Biomolecular Drug Research (BMWZ) and Institute for Organic Chemistry, Gottfried-Wilhelm-Leibniz University Hannover, Schneiderberg 38, 30167, Hannover, Germany.
Carsten ZeilingerCentre of Biomolecular Drug Research (BMWZ) and Institute for Organic Chemistry, Gottfried-Wilhelm-Leibniz University Hannover, Schneiderberg 38, 30167, Hannover, Germany. zeilinger@cell.uni-hannover.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Telomerase reverse transcriptase is crucial for cellular development, regeneration, and disease processes. Strategies for both telomerase activation and inhibition have been intensively explored in the past decades. In this study, we present a highly miniaturized, microarray-based assay designed to identify compounds that target telomerase. The active protein was either recombinantly derived from E. coli or obtained from cell lysates of human cancer cell lines and mouse cells expressing telomerase. Using non-contact spotter technology, these lysates or purified telomerase proteins were transferred onto nitrocellulose pads on a microarray. A telomerase binding assay, incorporating fluorescent labelled primer, the template RNA telomerase RNA component, and fluorescent labelled nucleotide as a primer cocktail, was conducted in incubation chambers. Binding of this primer cocktail to spotted telomerase from cell lysates, and from purified recombinant telomerase resulted in an increase in bound fluorescence. Epigallocatechin gallate, a known telomerase inhibitor, reduced this fluorescence in a dose-dependent manner with micromolar affinity. The inhibitory effect on telomerase was validated by thermophoresis and its impact on activity was shown in a Telomerase Repeated Amplification Protocol (TRAP) assay. Additional screening identified that 4'-iodo cytochalasin H inhibits primer cocktail binding to cell lysate in the low micromolar range. Molecular modeling and docking pinpointed a putative binding site for epigallocatechin gallate in a human telomerase homologue, and a putative binding site for 4'-iodo cytochalasin H. In summary, we developed an assay that can be employed to discover new telomerase inhibitors and that will serve as a valuable tool for screening of activators.

Indexed as

TelomeraseAnimalsCatechinCell Line, TumorEnzyme InhibitorsHumansMiceProtein BindingCatechinEnzyme Inhibitorsepigallocatechin gallateTelomerase

Identifiers

PMID40467649
PMCPMC12137546

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.